Use of SSRIs during pregnancy

November 2009
Travel Medicine Advisor;Nov2009 Supplement, p1
The article focuses on a study from Denmark which reveals that use of selective serotonin reuptake inhibitors (SSRIs) such as sertraline and citalopram during pregnancy results to higher risk of septal heart defects in children. It states that the research was based from the Danish nationwide registry's data from 1996 to 2003. The authors note the lack of association of heart defects in paroxetine and add that greatest risk occurs when more than one drug was taken during pregnancy.


Related Articles

  • Use of SSRIs during pregnancy. Elliott, William T. // Primary Care Reports;Nov2009 Pharmacology Watch, p1 

    The article discusses the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. It explains that SSRIs are associated with septal heart defects, which pregnant women can obtain through taking sertraline and citalopram based on a study from Denmark. The highlight of the...

  • Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Pilgrim, Jennifer; Gerostamoulos, Dimitri; Drummer, Olaf // International Journal of Legal Medicine;Nov2011, Vol. 125 Issue 6, p803 

    In the Australian state of Victoria, all fatalities that were recorded from 2002 through to 2008 involving the use of certain serotonin active drugs (tramadol, venlafaxine, fluoxetine, sertraline, citalopram and paroxetine), were reviewed to assess the incidence of contraindicated or ill advised...

  • Perioperative SSRI use increases risk of adverse outcomes.  // Reactions Weekly;5/4/2013, Issue 1451, p1 

    The article discusses a study which revealed an increase in the risk of adverse outcome in patients receiving selective serotonin uptake inhibitors (SSRIs) during the perioperative period.

  • Use of SSRIs during pregnancy was not associated with increased risk for stillbirth neonatal mortality. Jimenez-Solem, E.; Budenholzer, Brian // Annals of Internal Medicine;6/18/2013, Vol. 158 Issue 12, pJC12 

    The article presents an overview of a retrospective, population-based cohort study which examined the risk of using selective serotonin reuptake inhibitors (SSRI) during pregnancy. Stillbirth and neonatal death as a result of exposure to either fluoxetine, citalopram, paroxetine, sertraline or...

  • SSRIs in pregnancy: risk of early infant morbidity and mortality.  // Reactions Weekly;6/14/2012, Issue 1410, p2 

    The article focuses on a study which examined the association between maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and increased morbidity and mortality risks during the early years of life.

  • Antidepressants did not increase risk for bone loss.  // Endocrine Today;Oct2013, Vol. 11 Issue 10, p20 

    The article discusses the results of a study which showed that serotonin reuptake inhibitors and tricyclic antidepressants did not increase risk for bone loss, referencing a research by Susan J. Diem and colleagues, published in the "Journal of Clinical Endocrinology and Metabolism."

  • Desvenlafaxine Extended Release. Yang, Lily P. H.; Plosker, Greg L. // CNS Drugs;2008, Vol. 22 Issue 12, p1061 

    â–´ Desvenlafaxine extended release (ER) is a oncedaily selective serotonin-noradrenaline (norepinephrine) reuptake inhibitor approved in the US for the treatment of major depressive disorder in adult patients. â–´ In two of three well designed, 8-week clinical trials, desvenlafaxine ER...

  • Study finds link between SSRIs and congenital heart defects.  // Reactions Weekly;10/3/2009, Issue 1272, p1 

    The article discusses research in the U.S. and Denmark on the association of selective serotonin reuptake inhibitor (SSRI) with the prevalence of congenital heart defects. It references a study by C. Chamber, published in the September 2009 issue of the "British Medical Journal." In the first...

  • More evidence of the effect of SSRIs on hot flushes.  // Menopause International;Mar2011, Vol. 17 Issue 1, p3 

    The article presents the result of a study which suggested the therapeutic use of selective serotonin reuptake inhibitor (SSRI) in reducing the frequency and complication of menopausal hot flushes. The researchers compared menopausal women who received SSRI escitalopram with those who are under...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics